Literature DB >> 11920258

The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells.

A Pierce1, D L Smith, L V Jakobsen, A D Whetton, E Spooncer.   

Abstract

INTRODUCTION: The causative oncogene in CML is the BCR/ABL protein tyrosine kinase. This stem cell disease is often treated with interferon alpha (IFN-alpha) which can initiate haematological and cytological remission which is associated with increased survival. There is however no clear indication of why CML cells are more responsive to IFN-alpha.
MATERIALS AND METHODS: To establish if BCR/ABL increases the sensitivity of multipotent cells to IFN-alpha a temperature sensitive mutant of BCR/ABL was expressed in the multipotent haemopoietic stem cell line FDCP-Mix. The effect of IFN-alpha in terms of proliferation, induction of apoptosis, changes in cell cycle inhibitor proteins, and differentiation was assessed by [3H]thymidine incorporation, Annexin V and Western blot analysis.
RESULTS: When the BCR/ABL tyrosine kinase was activated, the IFN-alpha-induced inhibition on the growth rate of the FDCP-Mix cell population was more marked than in control populations. The BCR/ABL-mediated effect was due to decreased rates of DNA synthesis. There was no IFN-alpha-mediated induction of apoptosis. This enhanced BCR/ABL mediated growth inhibition occurred over a range of growth factor concentrations and was independent of changes in p21(Cip1) and p27(Kip) levels. When FDCP-Mix cells were induced to differentiate into mature macrophages and neutrophils in the presence of IFN-alpha, there was increased sensitivity to IFN-alpha that was independent of BCR/ABL activity.
CONCLUSION: BCR/ABL PTK expression in this primitive multipotent haematopoietic cell line results in an enhanced response to IFN-alpha. In contrast, the more mature myeloid progenitor cells are equally responsive to this growth inhibitor. This data may explain some of the clinical effects of IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11920258     DOI: 10.1038/sj.thj.6200114

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  5 in total

Review 1.  The paradox of response and survival in cancer therapeutics.

Authors:  Carol Ann Huff; William Matsui; B Douglas Smith; Richard J Jones
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia.

Authors:  Edgar Faber; Adam Kuba; Jana Zapletalová; Martina Divoká; Šárka Rožmanová; Peter Rohoň; Milena Holzerová; Marie Jarošová; Karel Indrák
Journal:  J Interferon Cytokine Res       Date:  2011-12-22       Impact factor: 2.607

3.  Cancer Stem Cells: From Bench to Bedside.

Authors:  Richard J Jones; William Matsui
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

4.  Mathematical model for chemotherapeutic drug efficacy in arresting tumour growth based on the cancer stem cell hypothesis.

Authors:  R Ganguly; I K Puri
Journal:  Cell Prolif       Date:  2007-06       Impact factor: 6.831

5.  Activation of the Hedgehog pathway in chronic myelogeneous leukemia patients.

Authors:  Bing Long; Huanling Zhu; Cuixia Zhu; Ting Liu; Wentong Meng
Journal:  J Exp Clin Cancer Res       Date:  2011-01-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.